Changes in Hong Kong stocks | Federal Pharmaceuticals (03933) rose more than 3%, and the winning bidder in Group A across the insulin collection line is optimistic about its accelerated release
Federal Pharmaceuticals (03933) rose more than 3%. As of press release, it rose 3.41% to HK$9.71, with a turnover of HK$22.403,900.
Federal Pharmaceuticals (03933.HK): Amoxicillin Clavulanate Potassium Tablets passed the consistent evaluation of generic drug quality and efficacy
On April 24, Gelonghui Pharmaceuticals (03933.HK) announced that amoxicillin clavulanate potassium tablets (specification: 0.375g) declared by the Zhongshan Branch of Zhuhai Federal Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, were approved by the China National Drug Administration and passed the consistent evaluation of the quality and efficacy of generic drugs. Amoxicillin clavulanate potassium tablets are a penicillin-type broad-spectrum antibiotic. Clinically, it is commonly used to treat infections caused by beta-lactamase-producing bacteria, such as respiratory infections, skin and soft tissue infections, and urinary infections. Its curative effect is clear, safe and reliable, and is clinically based
Guojin Securities: Continued increase in domestic insulin share is expected to drive continued growth in performance
Since May 2022, national special insulin collection has been launched in various provinces and cities. While the price of insulin products has declined, the domestic substitution process has greatly accelerated.
Federal Pharmaceuticals (03933.HK): The company's insulin products are to be selected for centralized drug procurement in the country
Gelonghui, April 23 | Federal Pharmaceutical (03933.HK) announced that the company's wholly-owned subsidiaries, Zhuhai Federal Pharmaceutical Co., Ltd. and the Zhongshan Branch of Zhuhai Federal Pharmaceutical Co., Ltd. participated in the bidding process for centralized national drug procurement (insulin special continuation) (“insulin special continuation”) organized by the State Organization Drug Joint Procurement Office on April 23, 2024. The company's insulin products are to be selected for this centralized procurement. All of the company's insulin products participated in this insulin collection competition, and all products were selected in Class A. In 2023, the company will sell the total sales of the products to be selected above
Hong Kong Stock Concept Tracking | Insulin Collection Renewal Results Announced, All 13 Companies Won Bids to Benefit Domestic Companies (with Concept Shares)
The agency determined that domestic insulin companies with the advantages of production capacity scale, brand stickiness, and sales coverage are expected to clearly benefit.
Changes in Hong Kong stocks | Federal Pharmaceuticals (03933) rose more than 5%, diet pills welcome new catalytic companies, and GLP-1 pipelines are abundant
Federal Pharmaceuticals (03933) rose more than 5%. As of press release, it rose 5.2% to HK$9.92, with a turnover of HK$18.378 million.
[Broker Focus] China and Thailand International upgraded the target price of Federal Pharmaceuticals (03933) to HK$11.58 and upgraded the rating to “buy”
Jinwu Financial News | According to the Sino-Thai International Development Research Report, the operating revenue of Federal Pharmaceuticals (03933) in 2023 increased 21.2% year-on-year to 13.74 billion yuan (RMB, same below), slightly exceeding the forecast. The company's gross margin increased from 43.8% to 46.1% due to rising prices of intermediates and API products. The company's sales expense ratio decreased from 14.7% in 2022 to 11.6%, resulting in a year-on-year increase of 70.9% to about 2.7 billion yuan in net profit, exceeding expectations by 18.8%. Considering that 2023 revenue slightly exceeded expectations, the bank is forecasting 2024-25E revenue
Federal Pharmaceuticals (03933) plans to pay a final dividend of $0.28 per share
Federal Pharmaceuticals (03933) announced that it intends to pay a final dividend of RMB 0.28 per share.
Zhongtai Securities: Q1 results are about to be implemented, gradually focus on the pharmaceutical sector and individual stocks with improved Q2 performance
Zhongtai Securities said that at present, the overall market is still at a relative bottom. After experiencing a long-term correction, the pharmaceutical sector is also at multiple bottoms in terms of fundamentals, policies, and capital, and is firmly optimistic about the pharmaceutical sector market throughout the year.
CICC: Maintaining Federal Pharmaceuticals' (03933) “Outperform the Industry” rating target price increase by 31% to HK$10.5
Federal Pharmaceuticals (03933)'s revenue in 2023 is in line with this reservation. As intermediate prices remain high and production is at full capacity throughout the year, net profit is significantly higher than the forecast.
UNITED LAB To Go Ex-Dividend On June 17th, 2024 With 0.30872 HKD Dividend Per Share And 0.13231 HKD Special Dividend Per Share
March 27th - $UNITED LAB(03933.HK)$ is trading ex-dividend on June 17th, 2024. Shareholders of record on June 18th, 2024 will receive 0.30872 HKD dividend per share and 0.13231 HKD special dividen
The United Laboratories International's 2023 Profit Rises on Higher Revenue
The United Laboratories International Holdings' (HKG:3933) attributable profit increased to 2.70 billion yuan, or 1.4867 yuan per share, in 2023, from 1.58 billion yuan, or 0.8689 yuan per share, in 2
[Hong Kong Stock Connect] Federal Pharmaceuticals (03933) increased profit by 70.9% last year to RMB 2,701 billion and distributed a total of 40 points with a special dividend
Jinwu Financial News | Federal Pharmaceuticals (03933) announced that in 2023, company owners should account for the current year's profit of RMB 2,701 billion (RMB, same below), up 70.9% year on year; basic profit per share was 148.67 points, up 71.1% year on year; the board of directors proposed to pay a final dividend of RMB 28 points per share for the year ended December 31, 2023, and a special dividend of RMB 12 points per share. Together with the interim dividend of RMB 12 per share already paid, the annual dividend is RMB 52 cents per share. During the period, the company achieved revenue of 13.74 billion yuan, an increase of 21.2 billion yuan over the previous year
Federal Pharmaceuticals (03933.HK): Net profit increased 70.9% to 2.701 billion yuan in 2023, R&D investment increased 36.2% year-on-year
On March 27, Gelonghui (03933.HK) announced its 2023 annual results announcement. During the year under review, the Group recorded a turnover of approximately RMB 13.794 billion, an increase of about 21.2% over 2022. Profit attributable to company owners was RMB 2,701 billion, an increase of 70.9% over the previous year. Earnings per share were RMB 148.67 cents. The Board recommended a final dividend of RMB 28 points per share and a special dividend of RMB 12 points per share. Together with the interim dividend of RMB 12 per share already paid, the annual dividend is RMB 52 cents per share. GLP-1 Pharmacopoeia
Federal Pharmaceuticals (03933) announced annual results. Profit attributable to shareholders was 2.701 billion yuan, an increase of 70.9% over the previous year, with proposed final interest of 28 points per share and special interest of 12 points per sh
Federal Pharmaceuticals (03933) announced its 2023 annual results announcement, with revenue of about 13.74 billion yuan (RMB, below...
UNITED LAB: 2023 ANNUAL RESULTS ANNOUNCEMENT
United Laboratories International Holdings' (HKG:3933) Five-year Earnings Growth Trails the 19% YoY Shareholder Returns
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But on a lighter note, a good company can see its share price rise well over
Hong Kong stocks closed (03.15) | Hang Seng Index closed down 1.42%, copper stocks rallied in the afternoon, and medicine continued to fall
The three major indices of Hong Kong stocks continued the recent pullback, showing a weak and volatile trend throughout the day. Among them, the Hengke Index showed the weakest performance. At one point, it fell more than 3% intraday.
The United Laboratories International Forecasts Profit Surge in 2023
The United Laboratories International Holdings (HKG:3933) expects a net profit of about 2.6 billion yuan for 2023, compared with about 1.6 billion yuan of profit in 2022, according to a Thursday Hong
[Yingxi Shares] Federal Pharmaceuticals (03933) rose 4.72%. Profit is expected to increase to RMB 2.6 billion last year
Jinwu Financial News | Federal Pharmaceuticals (03933) had a strong opening. As of press release, it rose 4.72% to HK$8.87, with a turnover of HK$9.23 million. According to the news, the company announced that the group expects to make a profit of about RMB 2.6 billion in 2023, while profit of about RMB 1,581 billion in 2022. According to the announcement, the increase in profit was mainly due to the steady increase in the turnover of the Group's various business segments during the year; among them, sales of intermediate products and APIs continued to grow, and rising demand represented by overseas markets led to a steady rise in market prices for related products. In addition, sales guarantee for animal insurance products during the year
No Data